TY - JOUR
T1 - Corrigendum to "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)
T2 - An update (2014-2018)" [Clin. Neurophysiol. 131 (2020) 474-528]
AU - Lefaucheur, Jean-Pascal
AU - Aleman, André
AU - Baeken, Chris
AU - Benninger, David H
AU - Brunelin, Jérôme
AU - Di Lazzaro, Vincenzo
AU - Filipović, Saša R
AU - Grefkes, Christian
AU - Hasan, Alkomiet
AU - Hummel, Friedhelm C
AU - Jääskeläinen, Satu K
AU - Langguth, Berthold
AU - Leocani, Letizia
AU - Londero, Alain
AU - Nardone, Raffaele
AU - Nguyen, Jean-Paul
AU - Nyffeler, Thomas
AU - Oliveira-Maia, Albino J
AU - Oliviero, Antonio
AU - Padberg, Frank
AU - Palm, Ulrich
AU - Paulus, Walter
AU - Poulet, Emmanuel
AU - Quartarone, Angelo
AU - Rachid, Fady
AU - Rektorová, Irena
AU - Rossi, Simone
AU - Sahlsten, Hanna
AU - Schecklmann, Martin
AU - Szekely, David
AU - Ziemann, Ulf
PY - 2020/5
Y1 - 2020/5
N2 - When referring to the study of Rutherford et al. (2015) on short- and long-term effects of rTMS in Alzheimer's disease, we erroneously stated in our article (Lefaucheur et al., 2020) that a clinical benefit on cognitive performance (tested by the Montreal Cognitive Assessment) was observed at weeks 2–3, only in the real stimulation condition during an initial sham-controlled 4-week period of treatment, and that then this benefit was prolonged by “2 additional weeks” of open-label real rTMS. In fact, this extended open-label treatment was administered for up to 19 months in multiple 2-week blocks with 2–7 months intervals between blocks and was not limited to a single additional 2-week block of treatment immediately following the original 4 weeks of treatment. Therefore, the results of that open-label extended follow-up study support the value of long-term maintenance treatment using multiple rTMS sessions rather than be interpreted as short-term 2-week extension.
AB - When referring to the study of Rutherford et al. (2015) on short- and long-term effects of rTMS in Alzheimer's disease, we erroneously stated in our article (Lefaucheur et al., 2020) that a clinical benefit on cognitive performance (tested by the Montreal Cognitive Assessment) was observed at weeks 2–3, only in the real stimulation condition during an initial sham-controlled 4-week period of treatment, and that then this benefit was prolonged by “2 additional weeks” of open-label real rTMS. In fact, this extended open-label treatment was administered for up to 19 months in multiple 2-week blocks with 2–7 months intervals between blocks and was not limited to a single additional 2-week block of treatment immediately following the original 4 weeks of treatment. Therefore, the results of that open-label extended follow-up study support the value of long-term maintenance treatment using multiple rTMS sessions rather than be interpreted as short-term 2-week extension.
KW - rTMS
KW - therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=85080122608&partnerID=8YFLogxK
U2 - 10.1016/j.clinph.2020.02.003
DO - 10.1016/j.clinph.2020.02.003
M3 - Comment/debate
C2 - 32122766
VL - 131
SP - 1168
EP - 1169
JO - Clinical Neurophysiology
JF - Clinical Neurophysiology
SN - 1388-2457
IS - 5
ER -